Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 1
1988 3
1989 4
1990 5
1992 4
1993 14
1994 22
1995 22
1996 37
1997 32
1998 41
1999 36
2000 38
2001 53
2002 45
2003 53
2004 73
2005 64
2006 83
2007 109
2008 121
2009 84
2010 93
2011 106
2012 104
2013 125
2014 104
2015 96
2016 106
2017 102
2018 114
2019 95
2020 85
2021 79
2022 61
2023 55
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

1,999 results

Results by year

Filters applied: . Clear all
Page 1
The vesicular monoamine transporter 2: an underexplored pharmacological target.
Bernstein AI, Stout KA, Miller GW. Bernstein AI, et al. Neurochem Int. 2014 Jul;73:89-97. doi: 10.1016/j.neuint.2013.12.003. Epub 2014 Jan 4. Neurochem Int. 2014. PMID: 24398404 Free PMC article. Review.
In the monoamine system, this process is carried out by the vesicular monoamine transporters (VMAT1 and VMAT2). These proteins are responsible for vesicular packaging of dopamine, norepinephrine, serotonin, and histamine. ...
In the monoamine system, this process is carried out by the vesicular monoamine transporters (VMAT1 and VMAT2). These …
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F, Luther K, Talreja O. Khorassani F, et al. Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299. Am J Health Syst Pharm. 2020. PMID: 31974564 Review.
PubMed, MEDLINE, and ClinicalTrials.gov were searched using the following keywords and MeSH terms: valbenazine, deutetrabenazine, tardive dyskinesia, VMAT2 inhibitors, and vesicular monoamine transporter 2 inhibitors. Randomized, double-blind, placebo-control …
PubMed, MEDLINE, and ClinicalTrials.gov were searched using the following keywords and MeSH terms: valbenazine, deutetrabenazine, tardive dy …
Vesicular monoamine transporter 2 mediates fear behavior in mice.
Branco RC, Burkett JP, Black CA, Winokur E, Ellsworth W, Dhamsania RK, Lohr KM, Schroeder JP, Weinshenker D, Jovanovic T, Miller GW. Branco RC, et al. Genes Brain Behav. 2020 Jun;19(5):e12634. doi: 10.1111/gbb.12634. Epub 2020 Jan 14. Genes Brain Behav. 2020. PMID: 31898856 Free PMC article.
A subset of people exposed to a traumatic event develops post-traumatic stress disorder (PTSD), which is associated with dysregulated fear behavior. Genetic variation in SLC18A2, the gene that encodes vesicular monoamine transporter 2 (VMAT2), has been report …
A subset of people exposed to a traumatic event develops post-traumatic stress disorder (PTSD), which is associated with dysregulated fear b …
Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2.
Kilbourn MR, Koeppe RA. Kilbourn MR, et al. ACS Chem Neurosci. 2019 Jan 16;10(1):25-29. doi: 10.1021/acschemneuro.8b00429. Epub 2018 Sep 10. ACS Chem Neurosci. 2019. PMID: 30198706 Review.
Positron emission tomography (PET) studies of the monoamine neurotransmitter systems in the human brain employ a variety of radiotracers targeting the many receptors, transporters, and enzymes present in monoaminergic neurons. One of these is the vesicular monoam …
Positron emission tomography (PET) studies of the monoamine neurotransmitter systems in the human brain employ a variety of radiotrac …
Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective.
Citrome L. Citrome L. Expert Rev Neurother. 2018 Apr;18(4):323-332. doi: 10.1080/14737175.2018.1455504. Epub 2018 Apr 2. Expert Rev Neurother. 2018. PMID: 29557243 Review.
Tardive dyskinesia (TD) is an iatrogenic movement disorder caused by exposure to dopamine receptor blocking agents. Two vesicular monoamine transporter type 2 (VMAT2) inhibitors for the treatment of TD were approved by the US Food and Drug Administration in 2 …
Tardive dyskinesia (TD) is an iatrogenic movement disorder caused by exposure to dopamine receptor blocking agents. Two vesicular …
Treatment of Tardive Dyskinesia.
Bashir HH, Jankovic J. Bashir HH, et al. Neurol Clin. 2020 May;38(2):379-396. doi: 10.1016/j.ncl.2020.01.004. Epub 2020 Feb 28. Neurol Clin. 2020. PMID: 32279716 Review.
The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission. Dopamine-depleting vesicular monoamine transporter type 2 inhibitors are considered the treatment of choice of TD....
The judicious use of DRBAs is key to the prevention of TD, reduction of disease burden, and achieving lasting remission. Dopamine-depleting …
Vesicular monoamine transporter 2 (SLC18A2) regulates monoamine turnover and brain development in zebrafish.
Baronio D, Chen YC, Decker AR, Enckell L, Fernández-López B, Semenova S, Puttonen HAJ, Cornell RA, Panula P. Baronio D, et al. Acta Physiol (Oxf). 2022 Jan;234(1):e13725. doi: 10.1111/apha.13725. Epub 2021 Aug 26. Acta Physiol (Oxf). 2022. PMID: 34403568
AIM: We aimed at identifying potential roles of vesicular monoamine transporter 2, also known as Solute Carrier protein 18 A2 (SLC18A2) (hereafter, Vmat2), in brain monoamine regulation, their turnover, behaviour and brain development using a novel zeb …
AIM: We aimed at identifying potential roles of vesicular monoamine transporter 2, also known as Solute Carrier protein …
Meta-Analysis: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders.
Behling E, Farhat LC, Landeros-Weisenberger A, Bloch MH. Behling E, et al. Mov Disord. 2022 Apr;37(4):684-693. doi: 10.1002/mds.28957. Epub 2022 Feb 22. Mov Disord. 2022. PMID: 35191552 Review.
Vesicular monoamine transporter type 2 (VMAT2) inhibitors may be an effective therapy for chronic tic disorders (CTD), including Tourette syndrome (TS), but there has not been a meta-analysis compiling available evidence from randomized controlled trials (RCT …
Vesicular monoamine transporter type 2 (VMAT2) inhibitors may be an effective therapy for chronic tic disorders (CTD), …
The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases.
Yulug B, Hanoglu L, Kilic E. Yulug B, et al. Med Chem. 2015;11(2):104-8. doi: 10.2174/1573406410666140925151845. Med Chem. 2015. PMID: 25256242 Review.
Neuropharmacological relation of religious belief supports the role of dopaminergic activation as the leading neurochemical feature. However, vesicular monoamine transporter-2 (VMAT-2) has been shown to be responsible for removing of neurotransmitters such as …
Neuropharmacological relation of religious belief supports the role of dopaminergic activation as the leading neurochemical feature. However …
1,999 results